DOI:
10.1055/s-00000088
TumorDiagnostik & Therapie
LinksClose Window
References
Smith I et al.
2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Lancet 2007;
369: 29-36
We do not assume any responsibility for the contents of the web pages of other providers.